In the BioHarmony Drug Report Database
Perphenazine
Trilafon (perphenazine) is a small molecule pharmaceutical. Perphenazine was first approved as Trilafon on 1982-01-01. It is used to treat huntington disease, nausea, psychotic disorders, reye syndrome, and schizophrenia amongst others in the USA. The pharmaceutical is active against D(2) dopamine receptor. In addition, it is known to target 5-hydroxytryptamine receptor 2C, 5-hydroxytryptamine receptor 6, histamine H1 receptor, 5-hydroxytryptamine receptor 2A, and 5-hydroxytryptamine receptor 7.
Trade Name
|
Trilafon |
|---|---|
Common Name
|
perphenazine |
ChEMBL ID
|
CHEMBL567 |
Indication
|
huntington disease, nausea, psychotic disorders, reye syndrome, schizophrenia, substance withdrawal syndrome, torticollis, tourette syndrome, vomiting |
Drug Class
|
Typical antipsychotic |
Image (chem structure or protein)